Month: November 2016

22 Nov 2016

AbbVie pangenotypic combination shows promising results for Hepatitis C

AbbVie is running three large clinical research studies currently where a combination of glecaprevir and pibrentasvir has cured at least 98% of people with hepatitis C.

“The results we announced today bring us closer to providing a potential pan-genotypic, once-daily treatment option with 8 weeks of therapy for people living without cirrhosis and who are new to treatment,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. “With our registrational program nearing completion, we’re on track to submit our next generation, pan-genotypic regimen to regulatory authorities by the end of this year in the U.S. and early 2017 in the European Union and Japan.”

For the full article please visit : https://news.abbvie.com/news/eight-weeks-treatment-with-abbvies-investigational-pan-genotypic-regimen-glecaprevirpibrentasvir-gp-achieved-high-svr-rates-across-all-major-genotypes-chronic-hepatitis-c.htm#.WDR6wO5Nj68.link

[image source : http://www.investors.com/]

18 Nov 2016

How 3-D printing can save lives in the medical field

For most people the concept of three-dimensional (3D) printing is still seen as something from a science fiction novel, but the medical world is busy embracing this technology and is a major driving force behind its growth.

Dr Thomas Bartel, section head of the Heart and Vascular Institute at Cleveland Clinic Abu Dhabi said the following : “In health care, 3-D printing’s most impressive function is its ability to replicate organs to help plan for or simulate surgeries. 3-D printing helps us personalise care while minimising risk.”

The costs related to 3-D printing have dropped considerably over the past 2 years and, according to consultants Frost & Sullivan, the 3-D printing industry alone will become a $6 billion market by 2025.

For the full article please visit : http://www.thenational.ae/arts-life/well-being/how-three-dimensional-printing-can-save-lives-in-the-medical-field

[image source : http://www.starinfranet.com/]

09 Nov 2016

TB Alliance partners with PepsiCo

TB Alliance is a not-for-profit organisation dedicated to the discovery and development of better, faster-acting, and affordable tuberculosis drugs that are available to those who need them. The organisation recently announced a partnership with beverage company PepsiCo with the sole purpose of improving the taste of treatment for children with TB.

“At PepsiCo, we saw a unique opportunity to leverage our R&D talent and flavor expertise to help improve the palatability of certain TB medicines,” said Dr. Mehmood Khan, Vice Chairman and Chief Scientific Officer, Global Research and Development, PepsiCo. “In collaboration with the TB Alliance team and others, we are hopeful that we can identify formulation changes that will make it easier for caregivers to administer TB medicines to children. Our work together has the potential to significantly improve the care and well-being of many TB patients and move us one step closer to the goal of eradicating TB in children.”

For the full story please visit : http://www.tballiance.org/news/tb-alliance-partners-pepsico-advance-fight-improved-medicines-children

[source : http://www.tballiance.org/]

04 Nov 2016

Merck’s new Alzheimer’s drug shows positive results

Merck’s new new Alzheimer’s drug (currently being evaluated in two Phase 3 clinical trials) has shown positive results in targeting the most visible sign of the disease in the patient’s brain. These results have had a very positive impact on the patient community suffering from Alzheimer’s as this could possibly be the first new treatment for the disease in more than a decade.

“We believe this research has the potential to contribute important evidence regarding the amyloid hypothesis, a leading scientific theory for what causes Alzheimer’s disease, and we look forward to seeing the data from our ongoing Phase 3 clinical trials,” Dr. Michael Egan, vice president of clinical development neurosciences at Merck Research Laboratories, said in a statement.

For the full story please visit : http://www.marketwatch.com/story/mercks-alzheimers-drug-data-fuel-hopes-for-new-treatment-2016-11-03

[source: http://www.marketwatch.com/]